• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Belviq Savings card program

Anonymous

Guest
Now that six months have lapsed, how has the promotional Belviq Savings card, driven revenue gain and market share?

Serious only please, Just want to get a idea of the extent of improvements to the metabolics business.
 

<



You're on the wrong message board, dickweed. This isn't a financial blog or investment group. All of the CP boards are strictly meant for hate mongering, bitching, and to help instill additional fear and loathing. Life is hell and we're all gonna die!!
 




You're on the wrong message board, dickweed. This isn't a financial blog or investment group. All of the CP boards are strictly meant for hate mongering, bitching, and to help instill additional fear and loathing. Life is hell and we're all gonna die!!

so glad to see such high levels of morale and professionalism, undoubtly signs of a brand that is improving and company that is reversing revenue decline.
 












you can do what you want with your discount cards, we have stifled your attempt to sTop our highly successful launch and we will continue to dominate you and the market. We have the best product and The best sales force. You can't win.
 




you can do what you want with your discount cards, we have stifled your attempt to sTop our highly successful launch and we will continue to dominate you and the market. We have the best product and The best sales force. You can't win.

Beating Eisai at pretty much anything doesn't require too much effort.